Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of NRIX is 30 and suggests 56% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell